A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Launched by ELI LILLY AND COMPANY · Sep 14, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called eltrekibart for adults who have moderate to severe hidradenitis suppurativa (HS), a skin condition that causes painful lumps and abscesses. The goal is to find out the best dose and how often the treatment should be given over a period of about 62 weeks, during which participants will make up to 31 visits to the study site.
To be eligible for this trial, participants need to have had HS for at least a year and have symptoms in at least two different areas of their body, with at least one area being more severe. They should also have had a limited response to antibiotics and must agree to use a daily antiseptic on their skin. However, the study isn't open to everyone; for instance, people with certain skin issues, recent surgeries, or specific health conditions may not qualify. If you or someone you know is considering joining this trial, it could be an opportunity to explore a new treatment option for managing HS.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have a diagnosis of HS for at least 12 months.
- • Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III.
- • Have an (abscess plus inflammatory nodule) count of at least 5.
- • Agree to use topical antiseptics daily.
- • Had an inadequate response or intolerance to a 28-day course of oral antibiotics.
- Exclusion Criteria:
- • Have more than 20 draining fistulae.
- • Have had surgical treatment for HS in the last 4 weeks before randomization.
- • Have an active skin disease or condition, that could interfere with the assessment of HS.
- • Have a current or recent acute, active infection.
- • Are immunocompromised.
- • Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.
About Eli Lilly And Company
Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Durham, North Carolina, United States
Milwaukee, Wisconsin, United States
Charleston, South Carolina, United States
Saint Louis, Missouri, United States
Boston, Massachusetts, United States
Westmead, New South Wales, Australia
Boston, Massachusetts, United States
Miami, Florida, United States
Farmington, Connecticut, United States
Melbourne, Victoria, Australia
Fremantle, Western Australia, Australia
Hamburg, , Germany
Bonn, Nordrhein Westfalen, Germany
Los Angeles, California, United States
Tampa, Florida, United States
Coral Gables, Florida, United States
Indianapolis, Indiana, United States
Winnipeg, Manitoba, Canada
Cleveland, Ohio, United States
Darlinghurst, New South Wales, Australia
Dallas, Texas, United States
Thessaloniki, , Greece
Omaha, Nebraska, United States
Fremont, California, United States
Miami, Florida, United States
Sydney, , Australia
Heraklion, , Greece
Birtinya, Queensland, Australia
Quebec City, Quebec, Canada
Katowice, , Poland
Frankfurt Am Main, Hessen, Germany
Portsmouth, New Hampshire, United States
Hialeah, Florida, United States
Murfreesboro, Tennessee, United States
Rogers, Arkansas, United States
Phoenix, Arizona, United States
Charlotte, North Carolina, United States
Sandy Springs, Georgia, United States
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Barrie, Ontario, Canada
Tampa, Florida, United States
Gdansk, Pomorskie, Poland
Louisville, Kentucky, United States
North Little Rock, Arkansas, United States
Fredericton, New Brunswick, Canada
South Jordan, Utah, United States
Tampa, Florida, United States
Margate, Florida, United States
Sugarloaf, Pennsylvania, United States
Hamburg, , Germany
Mayfield Heights, Ohio, United States
Saint Petersburg, Florida, United States
Durham, North Carolina, United States
Santa Monica, California, United States
Troy, Michigan, United States
Bochum, Nordrhein Westfalen, Germany
Fountain Valley, California, United States
Katowice, śląskie, Poland
Berlin, , Germany
Camp Hill, Pennsylvania, United States
Murfreesboro, Tennessee, United States
Miami, Florida, United States
Tampa, Florida, United States
Skokie, Illinois, United States
Portsmouth, New Hampshire, United States
Charlotte, North Carolina, United States
Camp Hill, Pennsylvania, United States
Columbia, South Carolina, United States
Frisco, Texas, United States
Spokane, Washington, United States
Wroclaw, Dolnoslaskie, Poland
London, Ontario, Canada
Erlangen, Bayern, Germany
Blankenfelde Mahlow, Brandenburg, Germany
Muenster, Westfalen, Germany
Athens, Attiki, Greece
Thessaloniki, Thessaloníki, Greece
Warszawa, Mazowieckie, Poland
Malbork, Pomorskie, Poland
Phoenix, Arizona, United States
Wroclaw, Dolnoslaskie, Poland
Murfreesboro, Tennessee, United States
Marriottsville, Maryland, United States
Bowling Green, Kentucky, United States
Nashville, Tennessee, United States
East Melbourne, Victoria, Australia
łódź, Lodzkie, Poland
Lodz, Lodzkie, Poland
Heraklion, Irakleío, Greece
Heraklion, , Greece
Patients applied
Trial Officials
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported